ArticleThe European respiratory journal2022
Benefits of specialist severe asthma management: demographic and geographic disparities.
Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Geographic Disparities in Evidence Investigating the Use of Biologics in Chronic Rhinosinusitis.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialePooled it
- Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma Registry.ERJ open research · 2026Article
- Maintenance oral steroids are not required in severe asthma.ERJ open research · 2024Article
- Impact of comorbidities on EQ-5D quality-of-life index in severe asthma.The journal of allergy and clinical immunology. Global · 2024Article
- Mixed-methods evaluation of an enhanced asthma biologics clinical pathway in the West Midlands UK.NPJ primary care respiratory medicine · 2024Article
- Severe asthma care trajectories: the French RAMSES cohort.ERJ open research · 2024Article
- Predictors of persistent poor control and validation of ASSESS score: Longitudinal 5-year follow-up of severe asthma cohort.The journal of allergy and clinical immunology. Global · 2024Article
- Consensus goals and standards for specialist cough clinics: the NEUROCOUGH international Delphi study.ERJ open research · 2023Article
- Asthma and Chronic Obstructive Pulmonary Disease.Clinics in chest medicine · 2023Review
- Ethnic variation in asthma healthcare utilisation and exacerbation: systematic review and meta-analysis.ERJ open research · 2023Review
- Article
- Roles of real-world evidence in severe asthma treatment: challenges and opportunities.ERJ open research · 2023Article
- An examination of factorial invariance of the Asthma Control Questionnaire among adults with severe asthma.PloS one · 2023Article
- Bringing the treatable traits approach to primary care asthma management.Frontiers in allergy · 2023Article
- Identification of autoantigens and their potential post-translational modification in EGPA and severe eosinophilic asthma.Frontiers in immunology · 2023Article
- [Consensus document for Severe Asthma. 2025 Update].Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThe benefits of specialist assessment and management have yet to be evaluated within the biologic era of UK severe asthma treatment, and potential disparities have not been considered.
methodsIn an uncontrolled before-and-after study, we compared asthma symptoms (Asthma Control Questionnaire-6 (ACQ-6)), exacerbations, unscheduled secondary care use, lung function (forced expiratory volume in 1 s (FEV
results1140 patients were followed-up for 1370 person-years from 12 specialist centres. At annual review, ACQ-6 score was reduced by a median (interquartile range (IQR)) of 0.7 (0.0-1.5), exacerbations by 75% (33-100%) and unscheduled secondary care by 100% (67-100%). FEV
conclusionsSpecialist assessment and management is associated with substantially improved patient outcomes, which are broadly consistent across demographic groups and are not restricted to those receiving biologic therapy. Significant variation exists between hospitals, which requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.